Showing 21 - 40 results of 59 for search '"Novo Nordisk"', query time: 0.06s Refine Results
  1. 21
  2. 22

    Utilities Associated with the Treatment of Growth Hormone Deficiency (GHD): A Time Trade-off (TTO) Study in the UK and Canada by Kirsch S, Butler G, Jensen LDF, Okkels A, Yssing C, Håkan-Bloch J

    Published 2025-01-01
    “…Susan Kirsch,1 Gary Butler,2 Lasse de Fries Jensen,3 Anna Okkels,4 Cecilie Yssing,4 Jonas Håkan-Bloch3 1Department of Pediatric Endocrinology, Hospital for Sick Children, Toronto and Oak Valley Health Hospital, Markham, Ontario, Canada; 2Department of Paediatric Endocrinology, University College London Hospitals, and UCL Great Ormond Street Institute of Child Health, London, UK; 3Novo Nordisk, Søborg, 2860, Denmark; 4EY Godkendt Revisionspartnerselskab, Frederiksberg, 2000, DenmarkCorrespondence: Lasse de Fries Jensen, Novo Nordisk, Vandtårnsvej 108-110, Søborg, 2860, Denmark, Tel +45 34482020, Email LDFJ@novonordisk.comPurpose: Growth hormone deficiency (GHD) causes decreased growth rate in children, resulting in short stature in childhood and adulthood. …”
    Get full text
    Article
  3. 23
  4. 24
  5. 25

    From economics to health outcomes: Delving into the significance of reduced insulin prices by M Leuschner, M Strydom, V Steenkamp

    Published 2024-08-01
    “… The recent substantial price reductions in insulin therapy by major manufacturers prompt an examination of their impact on South Africa (SA)’s healthcare. While Eli Lilly, Novo Nordisk, and Sanofi cut prices on long-acting basal insulin, among others, significantly, these insulins are not on SA’s Essential Medicines List (EML) for primary healthcare. …”
    Get full text
    Article
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34
  15. 35
  16. 36
  17. 37
  18. 38
  19. 39
  20. 40